Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics of a new sublingual formulation of temazepam

Summary

The pharmacokinetics of a new 10 mg sublingual tablet formulation of temazepam and those of a currently marketed 10 mg oral capsule formulation were evaluated in a group of ten healthy volunteers.

No significant differences were observed between the two formulations with respect to any of the pharmacokinetic parameters assessed. Lethargy and somnolence were reported on both capsule and tablet by several subjects at a time which corresponded with the maximum concentration of drug in plasma.

The data indicate that the sublingual tablet and orally administered capsule have a similar pharmacokinetic and pharmacodynamic profile.

This is a preview of subscription content, log in to check access.

References

  1. Badcock NR, Pollard AC (1982) Micro-determination of clonazepam in plasma or serum by electron-capture gas-liquid chromatography. J Chromatogr 230: 353–361

  2. Bolton S (1984) Pharmaceutical statistics. Marcel Dekker, New York

  3. Ghabrial H, Desmond PV, Watson KJR, Gijsbers AJ, Harman PJ, Breen KJ, Mashford ML (1986) The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 30: 93–97

Download references

Author information

Additional information

‘Normison’ (Wyeth)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Russell, W.J., Badcock, N.R., Frewin, D.B. et al. Pharmacokinetics of a new sublingual formulation of temazepam. Eur J Clin Pharmacol 35, 437–439 (1988). https://doi.org/10.1007/BF00561380

Download citation

Key words

  • temazepam
  • formulations
  • pharmacokinetics